ABEO - Abeona Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

14.20

-0.55 (-3.73%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	14.75
Open	14.65
Bid	13.85 x 800
Ask	14.85 x 2900
Day's Range	14.20 - 14.75
52 Week Range	7.01 - 22.75
Volume	442,658
Avg. Volume	981,725

Market Cap	671.735M
Beta	1.73
PE Ratio (TTM)	N/A
EPS (TTM)	-0.70
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	28.98

Trade prices are not sourced from all markets

All

News

Press Releases

Zacks6 days ago
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options
Abeona Therapeutics (ABEO) needs investors to pay close attention to the stock based on moves in the options market lately.
ACCESSWIRE12 days ago
Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities
Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...
Business Wire29 days ago
Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. – ABEO
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. (“Abeona” or the “Company”) (ABEO) into potential breaches of fiduciary duty by the Company’s Board of Directors (the “Board”). Newman Ferrara’s investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company.
ACCESSWIRElast month
57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS
Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Growing their sales consistently, and partnered with high-profile public clients, ORGS could be significantly undervalued with continued executiona and expansion. NEW YORK, NY / ACCESSWIRE / June 7, 2018 / The curative potential of gene and cell therapies has kept these new pharmaceutical products front and center for healthcare investors for the last 3 years.
GlobeNewswirelast month
Abeona Therapeutics Announces Upcoming Presentation at Jefferies 2018 Global Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
Benzingalast month
Abeona Therapeutics Has First-Mover Potential In Rare Diseases, Seaport Says In Bullish Initiation
Abeona Therapeutics Inc (NASDAQ: ABEO ), which employs gene and cell therapy for potential rare disease treatments, has a favorable risk-reward profile, according to Seaport Global Securities. The Analyst ...
ACCESSWIRElast month
Free Technical Research on Versartis and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).
Investopedialast month
9 Stocks Poised for Healthy Long-Term Gains
Stock investors looking for long-term growth plays in the health care space may seek guidance from Fidelity Fund manager Eddie Yoon, who oversees more than $35 billion in assets and leads the firm's health sector with a team of 12 investment professionals.
GlobeNewswire2 months ago
Abeona Therapeutics Announces Opening of Commercial Gene & Cell Therapy Manufacturing Facility in Ohio
--The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases. --Ribbon-cutting ceremony of gene and cell therapy ...
GlobeNewswire2 months ago
Analysis: Positioning to Benefit within Avadel Pharmaceuticals, Abeona Therapeutics, BanColombia S.A, Aercap Holdings N.V, Kite Realty Group Trust, and Credicorp — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, May 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Avadel ...
Motley Fool2 months ago
Here's Why Abeona Therapeutics Stock Dropped 12% Today
A clinical trial update for AB-102 didn't go far enough.
GlobeNewswire2 months ago
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
ABO-102 18- month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver volumes ...
GlobeNewswire2 months ago
Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting
NEW YORK and CLEVELAND, May 17, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening, rare, genetic ...
Thomson Reuters StreetEvents2 months ago
Edited Transcript of ABEO earnings conference call or presentation 14-May-18 2:00pm GMT
Q1 2018 Abeona Therapeutics Inc Earnings Call
Simply Wall St.2 months ago
Abeona Therapeutics Inc (NASDAQ:ABEO): Does The -41.52% Earnings Drop Reflect A Longer Term Trend?
Today I will take a look at Abeona Therapeutics Inc’s (NASDAQ:ABEO) most recent earnings update (31 March 2018) and compare these latest figures against its performance over the past fewRead More...
GlobeNewswire2 months ago
Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors
NEW YORK and CLEVELAND, May 14, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
Associated Press2 months ago
Abeona Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 18 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
GlobeNewswire2 months ago
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
Investor Conference Call on Monday, May 14th at 10:00 am ET NEW YORK and CLEVELAND, May 11, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company ...
GlobeNewswire2 months ago
Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights
NEW YORK and CLEVELAND, May 11, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
GlobeNewswire2 months ago
Abeona Therapeutics Announces Upcoming Presentations
NEW YORK and CLEVELAND, May 08, 2018-- Abeona Therapeutics Inc., a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
ACCESSWIRE3 months ago
Wired News – European Medicines Agency Granted Orphan Drug Designation for Abeona’s ABO-202 Gene Therapy Program in Batten Disease
LONDON, UK / ACCESSWIRE / April 24, 2018 / Active-Investors.com has just released a free research report on Abeona Therapeutics Inc. (NASDAQ: ABEO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ABEO as the Company's latest news hit the wire. On April 20, 2018, the Company announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona`s gene therapy program ABO-202 for the treatment of subjects with neuronal ceroid lipofuscinosis, also known as Batten Disease, a rare, fatal, autosomal recessive (inherited) disorder of the nervous system.
GlobeNewswire3 months ago
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation. NEW YORK and CLEVELAND, April 23, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical ...
GlobeNewswire3 months ago
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies ...
GlobeNewswire3 months ago
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
NEW YORK and CLEVELAND, April 20, 2018-- Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic ...
CNBC Videos3 months ago
Kensho's genetic engineering index
Kensho genetic engineering index has jumped 45% in the past year. It's top components, Uniqure NV, Sangamo Therapeutics and Abeona Therapeutics.